In a patient with major depressive disorder on aripiprazole (Abilify) 10 mg daily who is developing a gambling impulse‑control problem, how should the aripiprazole be tapered/discontinued and what alternative pharmacologic and non‑pharmacologic strategies can be used to manage her depression and gambling addiction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discontinue Aripiprazole Immediately and Transition to Evidence-Based Depression Management

Aripiprazole must be stopped immediately because it is causing gambling disorder—a recognized FDA-warned adverse effect that typically resolves within 30 days of discontinuation—and alternative depression treatments with equivalent or superior efficacy exist. 1, 2

Immediate Action: Aripiprazole Discontinuation

  • Stop aripiprazole now rather than tapering, as impulse-control symptoms (gambling, hypersexuality, compulsive behaviors) cease within 30 days of discontinuation in the majority of cases, and there is no evidence requiring a taper for this medication when used as an adjunct at 10 mg daily. 2

  • The FDA issued a formal warning in 2016 that aripiprazole causes compulsive behaviors including pathological gambling, and this risk exists even at low doses (as low as 5 mg daily) and in patients with no prior gambling history. 1, 2, 3

  • In systematic reviews of 59 cases, gambling symptoms appeared within 30 days of starting aripiprazole and resolved within 30 days of stopping, confirming a direct causal relationship. 2

  • Your patient's case mirrors published reports: gambling escalated from recreational to pathological approximately one year after starting aripiprazole 10 mg daily, consistent with the medication's dopamine D2/D3 partial agonist effects on mesolimbic reward pathways. 1, 4

Critical Safety Monitoring During Transition

  • Assess suicide risk immediately and at every visit during the medication transition, as suicide risk peaks during the first 1–2 months after any medication change, and your patient has already experienced gambling-related distress severe enough to warrant intervention. 5

  • Monitor for withdrawal dyskinesias, parkinsonian symptoms, or dystonias during the first month after stopping aripiprazole, though these are more common with abrupt discontinuation of higher-dose or long-term antipsychotic use. 6

First-Line Depression Treatment: Combination Therapy

Initiate combination therapy with both a second-generation antidepressant (SSRI or SNRI) and cognitive-behavioral therapy (CBT) concurrently, as this approach nearly doubles remission rates (57.5% vs 31.0%) compared to antidepressant monotherapy in patients with depression. 7, 5

Pharmacotherapy Selection

  • Start escitalopram 10 mg daily or sertraline 50 mg daily (titrate to 100–200 mg as needed), as these SSRIs have favorable tolerability profiles, lack sedating properties, and demonstrate equivalent efficacy to other second-generation antidepressants. 5

  • Alternatively, consider duloxetine 30–60 mg daily (an SNRI) if the patient has comorbid chronic pain, as SNRIs achieve higher remission rates (49% vs 42%) than SSRIs in this population. 5

  • Avoid bupropion initially despite its lower sexual dysfunction rates, because it may theoretically worsen impulse-control problems through dopaminergic mechanisms, though this risk is not well-established. 5

Psychotherapy Component

  • Begin structured CBT immediately and concurrently with the antidepressant, not sequentially, as CBT has moderate-quality evidence supporting effectiveness equivalent to antidepressants when used alone and superior outcomes when combined with medication. 7, 5

  • If CBT is unavailable, consider alternative evidence-based psychotherapies: Interpersonal Psychotherapy, Behavioral Activation, or Problem-Solving Therapy, all of which have demonstrated efficacy comparable to antidepressants. 5

Gambling Disorder Treatment

Add naltrexone 50 mg daily to target the gambling disorder specifically, as it has the strongest evidence for reducing gambling urges by blocking opioid receptors and reducing dopamine release in the nucleus accumbens. 7

  • Naltrexone must be combined with CBT targeting gambling-specific cognitive distortions; never prescribe naltrexone as monotherapy for gambling disorder. 7

  • Obtain baseline liver enzymes before starting naltrexone and repeat every 3–6 months, as naltrexone has been linked to hepatic injury at supratherapeutic doses. 7

  • Confirm the patient does not require opioid analgesics, as naltrexone will block opioid-mediated pain relief. 7

  • Add motivational interviewing if the patient shows ambivalence about stopping gambling, which is common in impulse-control disorders. 7

Treatment Algorithm

Week Action Monitoring
0 Stop aripiprazole immediately; start escitalopram 10 mg or sertraline 50 mg daily + naltrexone 50 mg daily; initiate concurrent CBT for both depression and gambling Baseline liver enzymes; suicide risk assessment
1–2 Assess for suicidality, agitation, irritability, gambling urges, and antidepressant adverse effects PHQ-9 score; gambling frequency/severity
4 Evaluate gambling symptom resolution (expected within 30 days of stopping aripiprazole) Gambling behavior assessment
6–8 Assess depression response (≥50% reduction in PHQ-9); if inadequate, increase SSRI dose or switch to SNRI PHQ-9, HAM-D, or MADRS; liver enzymes
12+ Continue treatment for 4–9 months after satisfactory response to prevent relapse Quarterly monitoring

Common Pitfalls to Avoid

  • Do not restart aripiprazole or try another atypical antipsychotic (quetiapine, brexpiprazole) for depression augmentation, as all dopamine partial agonists carry similar impulse-control risks, and your patient has already demonstrated vulnerability to this adverse effect. 7, 1, 2

  • Do not delay stopping aripiprazole to "taper gradually," as the gambling disorder will persist and potentially worsen, and there is no evidence that tapering reduces withdrawal symptoms at this dose when used as an adjunct. 2

  • Do not treat the gambling disorder in isolation without addressing the underlying depression, as both conditions share dysregulated reward circuitry and require integrated treatment. 6, 7

  • Do not prescribe naltrexone without concurrent behavioral therapy, as monotherapy has poor outcomes and the combination is essential for sustained remission. 7

  • Do not assume the gambling will resolve spontaneously after stopping aripiprazole; while the compulsive urges typically cease within 30 days, the patient may have developed a conditioned behavioral pattern requiring CBT to address gambling-specific cognitive distortions. 7, 2

Screening for Comorbidities

  • Screen systematically for ADHD, other impulse-control problems, compulsive symptoms, and substance use disorders, as gambling disorder frequently presents with these comorbidities and they share abnormalities in brain reward pathways (striatum) and loss of prefrontal cortex control over urges. 6, 7

References

Research

Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2017

Guideline

Diagnostic Criteria and Treatment Options for Major Depressive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Best Medication for Co-Occurring Gambling and Substance Use Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

In an adult woman with depression, methamphetamine use disorder, and gambling impulse‑control problems who is taking aripiprazole (Abilify) and escitalopram, should the first treatment step be to taper and discontinue aripiprazole to address the gambling behavior?
What is the incidence of impulse control disorders in a patient with a history of psychiatric treatment, including Selective Serotonin Reuptake Inhibitors (SSRIs), when considering the addition of aripiprazole to their regimen?
Can Abilify (aripiprazole) cause sexual impulsivity in patients, particularly those with a history of impulse control disorders or other psychiatric comorbidities?
In a female patient with major depressive disorder, methamphetamine use disorder, and aripiprazole‑induced compulsive gambling who is currently on aripiprazole (Abilify) and escitalopram, should aripiprazole be discontinued and replaced with bupropion while continuing CBT and vocational support?
How should I taper and discontinue aripiprazole (Abilify) in a depressed patient taking metoprolol, bupropion (Wellbutrin), clonidine, a proton‑pump inhibitor for reflux, and an unidentified anxiety medication?
Is bupropion a P‑glycoprotein (P‑gp) substrate and/or inhibitor, and how does co‑administration with sertraline affect P‑gp‑mediated transport at the blood‑brain barrier?
How should mild persistent allergic rhinitis be managed in a 29-year-old Filipino male?
Does co‑administration of an acidic beverage or food reduce lisdexamfetamine‑induced anxiety?
What pharmacokinetic interactions occur via cytochrome P450 enzyme modulation when sertraline and bupropion (Wellbutrin) are co‑administered?
For an adult with type 2 diabetes, how many weeks should the 5 mg weekly subcutaneous tirzepatide be maintained before escalating to the next dose?
How does Atruby (acoramidis) improve heart failure in adult patients with transthyretin amyloid cardiomyopathy who have heart‑failure symptoms or elevated N‑terminal pro‑B‑type natriuretic peptide?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.